Countable Labs Raises $26M in Funding Led by ARCH Venture Partners

The round also saw participation from F-Prime Capital and Primer Ventures.

The company plans to use the funds to support global expansion and develop specialized solutions using its 10-color technology for applications such as cell and gene therapy, minimal residual disease (MRD) testing, biomarker validation, vaccine quality control, and other healthcare uses.

Countable PCR is a scalable single-molecule testing technology designed to provide higher sensitivity and precision than traditional digital PCR. The platform does not require Poisson correction, standard curves, or complex interpretation, making results clearer and easier to use. It is built for research, translational science and industrial testing applications.

Countable PCR also supports molecular linkage analysis, which helps researchers study inherited genetic patterns and disease-related regions of the genome. With simple workflows, high throughput, broad dynamic range, and multiplexing capabilities, the technology helps laboratories detect rare events, gene fusions and markers of genome integrity across many sample types.

Chris Citraro has joined Countable Labs as Vice President of Global Sales. He brings nearly 20 years of experience selling advanced life sciences tools. Before joining Countable Labs, he worked at 10x Genomics in leadership roles focused on regional and biopharma sales. He also previously held sales positions at Agena Bioscience, Thermo Fisher Scientific, and MP Biomedicals. Citraro earned a bachelor’s degree in biological sciences from Ohio University.

"The future of genomic testing requires technologies that are simple, sensitive, and inexpensive, helping to democratize access to genomic diagnostics and high-volume genome-based clinical and industrial testing,” said Christopher Citraro, Vice President of Global Sales at Countable Labs. "Countable PCR is exactly that, a technological step change that bridges the gap between complex digital PCR and the discoveries of next-generation sequencing, delivering clear, unambiguous results at scale."

"Through our investment in Countable Labs, we aim to democratize access to new genomic tools, helping to bring rare event detection capabilities to customers around the world," said Robert Weisskoff, Ph.D., Senior Partner at F-Prime Capital. "From minimal residual disease testing to cell and gene therapy manufacturing to pathogen tracking, Countable PCR has the power and robustness to overtake many segments where digital PCR and next-generation sequencing currently dominate."

Read More:Rep AI Raises $6.2M in Funding Led by Silicon Road Ventures

"PCR technology is widespread, but ready for disruption from faster, less expensive, and more robust technologies that remove the ambiguity that has plagued the industry," said Corey Ritter, Partner at ARCH Venture Partners. "Countable Labs has completely reimagined PCR, creating a highly accurate, user-friendly solution ideal for distributed use across research, translational research, and industrial testing. These attributes position the company for long-term growth and success."

"2026 is a critical year for Countable Labs’ momentum. This financing gives us the resources to ensure every laboratory that could benefit from a more sensitive genomics measurement solution finds Countable PCR," said Giovanna Prout, Chief Executive Officer at Countable Labs. "Our initial studies with clinical samples and use cases validated the technology's robustness. Now we must develop and globally market new products for key customer segments, such as cell and gene therapy and MRD, where labs need easy-to-use precision measurement solutions that go beyond the capabilities of digital PCR.”

About Countable Labs

Founded in 2019 by Christina Fan and based in Palo Alto, Countable Labs develops precision biology measurement technology for applications such as cell and gene therapy, oncology, and molecular diagnostics. Its Countable PCR technology provides at least 10 times more sensitivity than traditional PCR methods, along with strong quantitative accuracy and broad dynamic range. This allows researchers and laboratories to detect and measure rare biological targets with greater confidence than existing digital PCR and next-generation sequencing technologies.

Read More:Garner Health Raises $100M in Series E Funding Led by Index Ventures